Antenatal screening for chromosomal abnormalities

• US 6,010,912 A
• Filed: 12/04/1995
• Issued: 01/04/2000
• Est. Priority Date: 11/28/1992
• Status: Expired due to Term

• Current Assignee: Johnson & Johnson Clinical Diagnostics Inc. (Johnson & Johnson)
• Original Assignee: Johnson & Johnson Clinical Diagnostics Inc. (Johnson & Johnson)
• Inventors: Davies, Christopher John
• Primary Examiner(s): SAUNDERS, DAVID A
• Application Number:
  US08/566,467
• Time in Patent Office: 1,492 Days
• Field of Search: 436/65, 436/86, 436/87, 436/131, 436/510, 436/518, 436/811, 436/817, 436/818, 364/413.09, 705/2
• US Class Current: 436/510
• CPC Class Codes: G01N 2800/368 Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
• CPC Class Codes: G01N 2800/387 Down syndrome; Trisomy 18; Trisomy 13
• CPC Class Codes: G01N 33/689 related to pregnancy or the gonads
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
• CPC Class Codes: G01N 33/743 Steroid hormones
• CPC Class Codes: G01N 33/76 Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
• CPC Class Codes: G16H 10/40 for data related to laboratory analysis, e.g. patient specimen analysis
• CPC Class Codes: Y10S 436/811 Test for named disease, body condition or organ function
• CPC Class Codes: Y10S 436/817 Steroids or hormones
• CPC Class Codes: Y10S 436/818 Human chorionic gonadotropin

Abstract

A method for antenatal screening for chromosomal abnormalities in which maternal blood from a pregnant woman is measured for levels of free beta hCG and at least a second serum marker and/or precursors and metabolites of these markers and the measured levels of these markers together with the gestational age of the pregnant woman are compared to reference values at various gestational ages of the levels for free beta hCG and the second serum marker in (a) pregnant women carrying foetuses having the abnormalitie(s) subject to the screen and (b) pregnant women carrying normal foetuses, the comparison being indicative of the risk of the pregnant woman carrying a foetus with an abnormality subject to the screen characterised in that the second serum marker is pregnancy associated plasma protein A (PAPPA) and the screen is carried out by the end of the thirteenth (13th) completed week of pregnancy.

Claims

1. A method for antenatal screening for a chromosomal abnormality in a fetus, comprising:

A) calculating a pregnant patient'"'"'s a priori risk of carrying a fetus having said chromosomal abnormality,

B) measuring said pregnant patient'"'"'s blood in the first trimester for a concentration of free beta hCG, its precursors and metabolites, or a mixture thereof,

C) measuring said pregnant patient'"'"'s blood in the first trimester for a concentration of pregnancy associated plasma protein A, its precursors and metabolites, or a mixture thereof,

D) calculating a normalized value for each of said concentrations from steps B) and C) by dividing said concentrations by a median value found in a population of women with unaffected pregnancies and same gestational age as said pregnant patient,

E) calculating a first probability that the normalized values are part of a bivariate Gaussian distribution of values found in pregnancies with said chromosomal abnormality,

F) calculating a second probability that the normalized values are a part of a bivariate Gaussian distribution of values found in unaffected pregnancies,

G) calculating a likelihood ratio, said likelihood ratio being the ratio of said first probability and said second probability, and

H) modifying the a priori risk by the likelihood ratio.

2. The method of claim 1 wherein the chromosomal abnormality is Down'"'"'s Syndrome.

3. The method of claim 1 wherein the chromosomal abnormality is selected from the group consisting of:

Edward'"'"'s Syndrome, Pateaus Syndrome, Turner Syndrome, Monosomy X, Kleinefelter'"'"'s Syndrome, and any combination thereof.

4. An apparatus comprising, a means adapted for receiving measurements of a pregnant woman'"'"'s maternal blood concentration of concentration of free beta hCG, its precursors and metabolites, or a mixture thereof, and a computer programmed to carry out the following activities:

A) determining a pregnant patient'"'"'s a priori risk of carrying a fetus having a chromosomal abnormality,

B) measuring said pregnant patients blood in the first trimester for a concentration of free beta hCG, its precursors and metabolites, or a mixture thereof,

C) measuring said pregnant patient'"'"'s blood in the first trimester for a concentration of pregnancy associated plasma protein A, its precursors and metabolites, or a mixture thereof,

D) calculating a normalized value for each of said concentrations from steps B) and C) by dividing said concentrations by a median value found in a population of women with unaffected pregnancies and same gestational age as said pregnant patient,

E) calculating a first probability that the normalized values are part of a bivariate Gaussian distribution of values found in pregnancies with said chromosomal abnormality,

F) calculating a second probability that the normalized values are a part of a bivariate Gaussian distribution of values found in unaffected pregnancies,

G) calculating a likelihood ratio, said likelihood ratio being the ratio of said first probability and said second probability, and

H) modifying the a priori risk by the likelihood ratio.